Larvol Delta - Brenig-Therapeutics-Announces-the-Initiation-of-FirstinHuman-Clinical-Trial-of-BT267-a-BestinClass-LRRK2-Inhibitor-for-Parkinson39s-Disease

BT-267 - Brenig Therap

https://www.prnewswire.com/news-releases/brenig-therapeutics-announces-the-initiation-of-first-in-human-clinical-trial-of-bt-267-a-best-in-class-lrrk2-inhibitor-for-parkinsons-disease-302315979.html

Nov 26, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next